Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En fase III-studie av Dato-DXd med eller uten Durvalumab sammenlignet med etterforskerens valg av kjemoterapi i kombinasjon med Pembrolizumab hos pasienter med PD-L1 positiv lokalt tilbakevendende inoperabel eller metastatisk trippelnegativ brystkreft

24. september 2026 oppdatert av: AstraZeneca

En fase III, åpen, randomisert studie av Datopotamab Deruxtecan (Dato-DXd) med eller uten Durvalumab sammenlignet med etterforskerens valg av kjemoterapi (Paclitaxel, Nab-paclitaxel eller Gemcitabin + Carboplatin) i kombinasjon med Pembrolizumab-L1 Positiv PD Lokalt tilbakevendende inoperabel eller metastatisk trippel-negativ brystkreft (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

Studieoversikt

Detaljert beskrivelse

The primary objective of the study is to demonstrate superiority of Dato-DXd + durvalumab relative to ICC + pembrolizumab by assessment of PFS as assessed by BICR in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

The study will be stratified based on geographic location (US/Canada/Europe vs. Dato-DXd monotherapy enrolling countries vs. rest of world), disease-free interval (DFI) history (de novo vs. prior DFI 6 to 12 months vs. prior DFI > 12 months), and prior PD-1/PD-L1 treatment for early stage TNBC (yes vs. no).

This study aims to see if Dato-DXd with durvalumab allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy and pembrolizumab. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.

Studietype

Intervensjonell

Registrering (Antatt)

625

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • CABA, Argentina, 1425
        • Rekruttering
        • Research Site
      • CABA, Argentina, 1414
        • Rekruttering
        • Research Site
      • CABA, Argentina, C1425
        • Tilbaketrukket
        • Research Site
      • CABA, Argentina, C1113AAE
        • Rekruttering
        • Research Site
      • Ciudad Autónoma Buenos Aires, Argentina, C1430EFA
        • Rekruttering
        • Research Site
      • Ciudad de Buenos Aires, Argentina, C1015ABO
        • Rekruttering
        • Research Site
      • Rosario, Argentina, 2000
        • Rekruttering
        • Research Site
      • San Nicolás de los Arroyos, Argentina, B2900
        • Tilbaketrukket
        • Research Site
      • Camperdown, Australia, 2050
        • Rekruttering
        • Research Site
      • Darlinghurst, Australia, 2010
        • Fullført
        • Research Site
      • Heidelberg, Australia, 3084
        • Fullført
        • Research Site
      • Melbourne, Australia, 3000
        • Rekruttering
        • Research Site
      • Nedlands, Australia, 6009
        • Rekruttering
        • Research Site
      • Waratah, Australia, 2298
        • Tilbaketrukket
        • Research Site
      • Barretos, Brasil, 14784-400
        • Rekruttering
        • Research Site
      • Curitiba, Brasil, 80730-150
        • Rekruttering
        • Research Site
      • Florianópolis, Brasil, 88034-000
        • Rekruttering
        • Research Site
      • Goiânia, Brasil, 74000-000
        • Rekruttering
        • Research Site
      • Itajaí, Brasil, 88301-220
        • Rekruttering
        • Research Site
      • Porto Alegre, Brasil, 90035-003
        • Rekruttering
        • Research Site
      • Recife, Brasil, 52010-075
        • Rekruttering
        • Research Site
      • São Paulo, Brasil, 01246-000
        • Rekruttering
        • Research Site
      • São Paulo, Brasil, 01317-001
        • Rekruttering
        • Research Site
      • Teresina, Brasil, 64049-200
        • Rekruttering
        • Research Site
    • Ontario
      • Barrie, Ontario, Canada, L4M 6M2
        • Rekruttering
        • Research Site
      • Hamilton, Ontario, Canada, L8V 5C2
        • Rekruttering
        • Research Site
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • Research Site
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Rekruttering
        • Research Site
      • Montreal, Quebec, Canada, H4A 3J1
        • Rekruttering
        • Research Site
      • Montreal, Quebec, Canada, H2X 0A9
        • Rekruttering
        • Research Site
      • Québec, Quebec, Canada, G1S 4L8
        • Rekruttering
        • Research Site
    • Saskatchewan
      • Regina, Saskatchewan, Canada, S4T 7T1
        • Rekruttering
        • Research Site
      • Saskatoon, Saskatchewan, Canada, S7N 4H4
        • Rekruttering
        • Research Site
      • Bacolod, Filippinene, 6100
        • Rekruttering
        • Research Site
      • Cebu City, Filippinene, 6000
        • Rekruttering
        • Research Site
      • City of Muntinlupa, Filippinene, 1780
        • Rekruttering
        • Research Site
      • Manila, Filippinene, 1000
        • Rekruttering
        • Research Site
      • Quezon City, Filippinene, 1112
        • Rekruttering
        • Research Site
      • San Juan City, Filippinene, 1502
        • Rekruttering
        • Research Site
    • Alabama
      • Daphne, Alabama, Forente stater, 36526
        • Rekruttering
        • Research Site
    • Arkansas
      • Springdale, Arkansas, Forente stater, 72762
        • Rekruttering
        • Research Site
    • California
      • Duarte, California, Forente stater, 91010
        • Tilbaketrukket
        • Research Site
      • Fountain Valley, California, Forente stater, 92708
        • Har ikke rekruttert ennå
        • Research Site
      • Glendale, California, Forente stater, 91204
        • Rekruttering
        • Research Site
      • Sacramento, California, Forente stater, 95817
        • Rekruttering
        • Research Site
      • Santa Rosa, California, Forente stater, 95403
        • Tilbaketrukket
        • Research Site
    • Colorado
      • Aurora, Colorado, Forente stater, 80012
        • Rekruttering
        • Research Site
      • Denver, Colorado, Forente stater, 80210
        • Har ikke rekruttert ennå
        • Research Site
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510
        • Rekruttering
        • Research Site
    • Florida
      • Altamonte Springs, Florida, Forente stater, 32701
        • Har ikke rekruttert ennå
        • Research Site
      • Jacksonville, Florida, Forente stater, 32256
        • Tilbaketrukket
        • Research Site
      • Miami, Florida, Forente stater, 33176
        • Rekruttering
        • Research Site
      • Palm Bay, Florida, Forente stater, 32909
        • Tilbaketrukket
        • Research Site
      • Plantation, Florida, Forente stater, 33324
        • Rekruttering
        • Research Site
    • Georgia
      • Atlanta, Georgia, Forente stater, 30318
        • Suspendert
        • Research Site
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96819
        • Tilbaketrukket
        • Research Site
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • Research Site
      • Decatur, Illinois, Forente stater, 62526
        • Tilbaketrukket
        • Research Site
      • Elmhurst, Illinois, Forente stater, 60126
        • Tilbaketrukket
        • Research Site
      • Naperville, Illinois, Forente stater, 60540
        • Tilbaketrukket
        • Research Site
    • Indiana
      • New Albany, Indiana, Forente stater, 47150
        • Tilbaketrukket
        • Research Site
    • Iowa
      • Des Moines, Iowa, Forente stater, 50309
        • Rekruttering
        • Research Site
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40503
        • Tilbaketrukket
        • Research Site
      • Louisville, Kentucky, Forente stater, 40202
        • Tilbaketrukket
        • Research Site
      • Louisville, Kentucky, Forente stater, 40207
        • Tilbaketrukket
        • Research Site
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70809
        • Rekruttering
        • Research Site
      • Baton Rouge, Louisiana, Forente stater, 70808
        • Tilbaketrukket
        • Research Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21215
        • Tilbaketrukket
        • Research Site
      • Columbia, Maryland, Forente stater, 21044
        • Rekruttering
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02111
        • Tilbaketrukket
        • Research Site
      • Worcester, Massachusetts, Forente stater, 01655
        • Tilbaketrukket
        • Research Site
    • Michigan
      • Detroit, Michigan, Forente stater, 48201
        • Rekruttering
        • Research Site
      • Grand Rapids, Michigan, Forente stater, 49503
        • Tilbaketrukket
        • Research Site
    • Minnesota
      • Saint Paul, Minnesota, Forente stater, 55109
        • Rekruttering
        • Research Site
    • Mississippi
      • Hattiesburg, Mississippi, Forente stater, 39401
        • Tilbaketrukket
        • Research Site
    • Missouri
      • St Louis, Missouri, Forente stater, 63129
        • Rekruttering
        • Research Site
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87109
        • Rekruttering
        • Research Site
    • New York
      • Albany, New York, Forente stater, 12206
        • Tilbaketrukket
        • Research Site
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Research Site
      • Stony Brook, New York, Forente stater, 11794-7263
        • Rekruttering
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • Rekruttering
        • Research Site
      • Cincinnati, Ohio, Forente stater, 45245
        • Rekruttering
        • Research Site
      • Cleveland, Ohio, Forente stater, 44195
        • Rekruttering
        • Research Site
    • Pennsylvania
      • York, Pennsylvania, Forente stater, 17403
        • Tilbaketrukket
        • Research Site
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02903
        • Rekruttering
        • Research Site
    • Tennessee
      • Chattanooga, Tennessee, Forente stater, 37404
        • Rekruttering
        • Research Site
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Research Site
    • Texas
      • Dallas, Texas, Forente stater, 75246
        • Rekruttering
        • Research Site
      • Dallas, Texas, Forente stater, 75230
        • Tilbaketrukket
        • Research Site
      • Dallas, Texas, Forente stater, 75246
        • Tilbaketrukket
        • Research Site
      • El Paso, Texas, Forente stater, 79902
        • Rekruttering
        • Research Site
      • Flower Mound, Texas, Forente stater, 75028
        • Tilbaketrukket
        • Research Site
      • Fort Worth, Texas, Forente stater, 76104
        • Tilbaketrukket
        • Research Site
      • Houston, Texas, Forente stater, 77054
        • Tilbaketrukket
        • Research Site
      • Houston, Texas, Forente stater, 77090
        • Tilbaketrukket
        • Research Site
      • Houston, Texas, Forente stater, 77098
        • Tilbaketrukket
        • Research Site
      • Kingwood, Texas, Forente stater, 77339
        • Tilbaketrukket
        • Research Site
      • McKinney, Texas, Forente stater, 75071
        • Tilbaketrukket
        • Research Site
      • Sugar Land, Texas, Forente stater, 77479
        • Rekruttering
        • Research Site
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22903
        • Rekruttering
        • Research Site
      • Fairfax, Virginia, Forente stater, 22031
        • Rekruttering
        • Research Site
      • Midlothian, Virginia, Forente stater, 23114
        • Rekruttering
        • Research Site
      • Norfolk, Virginia, Forente stater, 23502
        • Rekruttering
        • Research Site
      • Roanoke, Virginia, Forente stater, 24014
        • Rekruttering
        • Research Site
    • Washington
      • Tacoma, Washington, Forente stater, 98405
        • Rekruttering
        • Research Site
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53792
        • Tilbaketrukket
        • Research Site
      • Lille, Frankrike, 59000
        • Rekruttering
        • Research Site
      • Lyon, Frankrike, 69373
        • Rekruttering
        • Research Site
      • Montpellier, Frankrike, 34298
        • Rekruttering
        • Research Site
      • Paris, Frankrike, 75020
        • Rekruttering
        • Research Site
      • Saint-Herblain, Frankrike, 44805
        • Rekruttering
        • Research Site
      • Toulouse, Frankrike, 31059
        • Rekruttering
        • Research Site
      • Vandœuvre-lès-Nancy, Frankrike, 54511
        • Rekruttering
        • Research Site
      • Villejuif, Frankrike, 94800
        • Rekruttering
        • Research Site
      • Hong Kong, Hong Kong, 999077
        • Rekruttering
        • Research Site
      • Calicut, India, 673601
        • Tilbaketrukket
        • Research Site
      • Chennai, India, 600031
        • Rekruttering
        • Research Site
      • Jaipur, India, 302004
        • Tilbaketrukket
        • Research Site
      • Kochi, India, 682027
        • Tilbaketrukket
        • Research Site
      • Kolkata, India, 700160
        • Tilbaketrukket
        • Research Site
      • Kottayam, India, 686008
        • Rekruttering
        • Research Site
      • Marg Jaipur, India, 302004
        • Rekruttering
        • Research Site
      • Mohali, India, 160055
        • Rekruttering
        • Research Site
      • Mysuru, India, 570017
        • Rekruttering
        • Research Site
      • Nagpur, India, 440001
        • Rekruttering
        • Research Site
      • Nashik, India, 422009
        • Rekruttering
        • Research Site
      • New Delhi, India, 11029
        • Rekruttering
        • Research Site
      • New Delhi, India, 110075
        • Rekruttering
        • Research Site
      • Puducherry, India, 605006
        • Rekruttering
        • Research Site
      • Surat, India, 395002
        • Rekruttering
        • Research Site
      • Thiruvananthapuram, India, 695011
        • Rekruttering
        • Research Site
      • Vadodara, India, 391760
        • Rekruttering
        • Research Site
      • Visakhapatnam, India, 530053
        • Tilbaketrukket
        • Research Site
      • Bergamo, Italia, 24127
        • Rekruttering
        • Research Site
      • Empoli, Italia, 50053
        • Rekruttering
        • Research Site
      • Milan, Italia, 20132
        • Rekruttering
        • Research Site
      • Milan, Italia, 20141
        • Rekruttering
        • Research Site
      • Modena, Italia, 41124
        • Tilbaketrukket
        • Research Site
      • Naples, Italia, 80131
        • Rekruttering
        • Research Site
      • Padova, Italia, 35128
        • Rekruttering
        • Research Site
      • Reggio Emilia, Italia, 42123
        • Rekruttering
        • Research Site
      • Roma, Italia, 00168
        • Rekruttering
        • Research Site
      • Rozzano, Italia, 20089
        • Rekruttering
        • Research Site
      • Akashi-shi, Japan, 673-8558
        • Rekruttering
        • Research Site
      • Bunkyō City, Japan, 113-8431
        • Rekruttering
        • Research Site
      • Bunkyō City, Japan, 113-8677
        • Rekruttering
        • Research Site
      • Chiba, Japan, 260-8717
        • Rekruttering
        • Research Site
      • Chūōku, Japan, 104-0045
        • Rekruttering
        • Research Site
      • Fukuoka, Japan, 811-1395
        • Rekruttering
        • Research Site
      • Fukushima, Japan, 960-1295
        • Rekruttering
        • Research Site
      • Gifu, Japan, 501-1194
        • Rekruttering
        • Research Site
      • Hidaka-shi, Japan, 350-1298
        • Rekruttering
        • Research Site
      • Hiroshima, Japan, 734-8551
        • Rekruttering
        • Research Site
      • Hiroshima, Japan, 730-8518
        • Rekruttering
        • Research Site
      • Isehara-shi, Japan, 259-1193
        • Rekruttering
        • Research Site
      • Kamogawa-shi, Japan, 296-8602
        • Rekruttering
        • Research Site
      • Kashiwa, Japan, 277-8577
        • Rekruttering
        • Research Site
      • Kitaadachi-gun, Japan, 362-0806
        • Rekruttering
        • Research Site
      • Kumamoto, Japan, 860-8556
        • Rekruttering
        • Research Site
      • Kurume-shi, Japan, 830-0011
        • Rekruttering
        • Research Site
      • Kōtoku, Japan, 135-8550
        • Rekruttering
        • Research Site
      • Matsuyama, Japan, 791-0280
        • Rekruttering
        • Research Site
      • Nagoya, Japan, 466-8560
        • Rekruttering
        • Research Site
      • Nagoya, Japan, 467-8602
        • Rekruttering
        • Research Site
      • Niigata, Japan, 951-8566
        • Rekruttering
        • Research Site
      • Nishinomiya-shi, Japan, 663-8501
        • Rekruttering
        • Research Site
      • Okayama, Japan, 700-8558
        • Rekruttering
        • Research Site
      • Osaka, Japan, 541-8567
        • Rekruttering
        • Research Site
      • Osakasayama-shi, Japan, 589-8511
        • Rekruttering
        • Research Site
      • Ota-shi, Japan, 373-8550
        • Rekruttering
        • Research Site
      • Sapporo, Japan, 003-0804
        • Rekruttering
        • Research Site
      • Sendai, Japan, 980-8574
        • Rekruttering
        • Research Site
      • Shinagawa-ku, Japan, 142-8666
        • Rekruttering
        • Research Site
      • Shinjuku-ku, Japan, 162-8655
        • Rekruttering
        • Research Site
      • Shinjuku-ku, Japan, 160-0023
        • Rekruttering
        • Research Site
      • Tsu, Japan, 514-8507
        • Rekruttering
        • Research Site
      • Tsukuba, Japan, 305-8577
        • Rekruttering
        • Research Site
      • Yokohama, Japan, 241-8515
        • Rekruttering
        • Research Site
      • Anyang, Kina, 455000
        • Rekruttering
        • Research Site
      • Beijing, Kina, 100044
        • Rekruttering
        • Research Site
      • Beijing, Kina, 100142
        • Rekruttering
        • Research Site
      • Bengbu, Kina, 233004
        • Rekruttering
        • Research Site
      • Changchun, Kina, 130021
        • Rekruttering
        • Research Site
      • Changsha, Kina, 410008
        • Rekruttering
        • Research Site
      • Changsha, Kina, 410013
        • Rekruttering
        • Research Site
      • Chengdu, Kina, 610000
        • Rekruttering
        • Research Site
      • Chengdu, Kina, 610041
        • Rekruttering
        • Research Site
      • Chongqing, Kina, 400030
        • Tilbaketrukket
        • Research Site
      • Fuzhou, Kina, 350014
        • Rekruttering
        • Research Site
      • Guangzhou, Kina, 510120
        • Rekruttering
        • Research Site
      • Guangzhou, Kina, 510060
        • Rekruttering
        • Research Site
      • Guangzhou, Kina, 510700
        • Rekruttering
        • Research Site
      • Hangzhou, Kina, 310009
        • Rekruttering
        • Research Site
      • Hangzhou, Kina, 310022
        • Rekruttering
        • Research Site
      • Hangzhou, Kina, 310016
        • Rekruttering
        • Research Site
      • Harbin, Kina, 150081
        • Rekruttering
        • Research Site
      • Hefei, Kina, 230031
        • Rekruttering
        • Research Site
      • Jinan, Kina, 250021
        • Aktiv, ikke rekrutterende
        • Research Site
      • Meizhou, Kina, 514031
        • Rekruttering
        • Research Site
      • Nanchang, Kina, 330009
        • Rekruttering
        • Research Site
      • Nanjing, Kina, 210009
        • Rekruttering
        • Research Site
      • Nanjing, Kina, 2100008
        • Rekruttering
        • Research Site
      • Nanning, Kina, 530021
        • Rekruttering
        • Research Site
      • Shandong, Kina
        • Rekruttering
        • Research Site
      • Shanghai, Kina, 200025
        • Rekruttering
        • Research Site
      • Shanghai, Kina, 200080
        • Fullført
        • Research Site
      • Shenyang, Kina, 110004
        • Rekruttering
        • Research Site
      • Taiyuan, Kina, 030000
        • Rekruttering
        • Research Site
      • Tianjin, Kina, 300000
        • Rekruttering
        • Research Site
      • Wenzhou, Kina, 325000
        • Rekruttering
        • Research Site
      • Wuhan, Kina, 430022
        • Rekruttering
        • Research Site
      • Wuhan, Kina, 430079
        • Rekruttering
        • Research Site
      • Xi'an, Kina, 710061
        • Rekruttering
        • Research Site
      • Xiamen, Kina, 361003
        • Rekruttering
        • Research Site
      • Xintai, Kina, 54031
        • Rekruttering
        • Research Site
      • Xuzhou, Kina, 221009
        • Rekruttering
        • Research Site
      • Zhanjiang, Kina, 524003
        • Rekruttering
        • Research Site
      • Zhengzhou, Kina, 450008
        • Rekruttering
        • Research Site
      • Zhengzhou, Kina, 450052
        • Rekruttering
        • Research Site
      • CD Mexico, Mexico, 04980
        • Rekruttering
        • Research Site
      • Guadalajara, Mexico, 44670
        • Tilbaketrukket
        • Research Site
      • Guadalajara, Mexico, 44638
        • Rekruttering
        • Research Site
      • Mexico City, Mexico, 0 3100
        • Rekruttering
        • Research Site
      • Mexico City, Mexico, 06760
        • Rekruttering
        • Research Site
      • México, Mexico, 04700
        • Rekruttering
        • Research Site
      • Tuxtla Gutiérrez, Mexico, 29090
        • Rekruttering
        • Research Site
      • Bialystok, Polen, 15-027
        • Tilbaketrukket
        • Research Site
      • Bydgoszcz, Polen, 85-796
        • Tilbaketrukket
        • Research Site
      • Gdansk, Polen, 80-952
        • Rekruttering
        • Research Site
      • Gdynia, Polen, 81-519
        • Tilbaketrukket
        • Research Site
      • Konin, Polen, 62-500
        • Tilbaketrukket
        • Research Site
      • Krakow, Polen, 31-501
        • Rekruttering
        • Research Site
      • Krakow, Polen, 31-115
        • Tilbaketrukket
        • Research Site
      • Legnica, Polen, 59-220
        • Tilbaketrukket
        • Research Site
      • Lodz, Polen, 90-302
        • Rekruttering
        • Research Site
      • Lublin, Polen, 20-090
        • Tilbaketrukket
        • Research Site
      • Przemyśl, Polen, 37-700
        • Tilbaketrukket
        • Research Site
      • Warsaw, Polen, 02-781
        • Rekruttering
        • Research Site
      • Wroclaw, Polen, 53-413
        • Tilbaketrukket
        • Research Site
      • Singapore, Singapore, 169610
        • Rekruttering
        • Research Site
      • Singapore, Singapore, 308433
        • Rekruttering
        • Research Site
      • Singapore, Singapore, 217562
        • Rekruttering
        • Research Site
      • Singapore, Singapore, 119228
        • Tilbaketrukket
        • Research Site
      • Barcelona, Spania, 8035
        • Rekruttering
        • Research Site
      • Barcelona, Spania, 08028
        • Tilbaketrukket
        • Research Site
      • Granada, Spania, 18016
        • Rekruttering
        • Research Site
      • Hospitalet deLlobregat, Spania, 08907
        • Rekruttering
        • Research Site
      • Madrid, Spania, 28007
        • Rekruttering
        • Research Site
      • Madrid, Spania, 28034
        • Tilbaketrukket
        • Research Site
      • Pamplona, Spania, 31008
        • Rekruttering
        • Research Site
      • Santander, Spania, 39008
        • Rekruttering
        • Research Site
      • Cardiff, Storbritannia, CF14 2TL
        • Rekruttering
        • Research Site
      • Chelsea, Storbritannia, SW3 6JJ
        • Rekruttering
        • Research Site
      • Leicester, Storbritannia, Le5 4PW
        • Rekruttering
        • Research Site
      • Liverpool, Storbritannia, L7 8YA
        • Avsluttet
        • Research Site
      • London, Storbritannia, EC1A 7BE
        • Rekruttering
        • Research Site
      • London, Storbritannia, SW17 0QT
        • Tilbaketrukket
        • Research Site
      • Oxford, Storbritannia, OX3 7LE
        • Suspendert
        • Research Site
      • Surrey, Storbritannia, GU2 7XX
        • Suspendert
        • Research Site
      • Sutton, Storbritannia, SM2 5PT
        • Rekruttering
        • Research Site
      • Taunton, Storbritannia, TA1 5DA
        • Rekruttering
        • Research Site
      • Busan, Sør -Korea, 49241
        • Fullført
        • Research Site
      • Daegu, Sør -Korea, 41404
        • Rekruttering
        • Research Site
      • Goyang-si, Sør -Korea, 10408
        • Rekruttering
        • Research Site
      • Seongnam-si, Sør -Korea, 13620
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 03080
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 06351
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 05505
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 06591
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 02841
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 06273
        • Rekruttering
        • Research Site
      • Cape Town, Sør-Afrika, 7570
        • Rekruttering
        • Research Site
      • Johannesburg, Sør-Afrika, 2013
        • Rekruttering
        • Research Site
      • Johannesburg, Sør-Afrika, 2196
        • Rekruttering
        • Research Site
      • Johannesburg, Sør-Afrika, 2193
        • Rekruttering
        • Research Site
      • Paarl, Sør-Afrika, 7646
        • Rekruttering
        • Research Site
      • Pretoria, Sør-Afrika, 0081
        • Rekruttering
        • Research Site
      • Pretoria, Sør-Afrika, 0081
        • Fullført
        • Research Site
      • Hsinchu, Taiwan, 300
        • Rekruttering
        • Research Site
      • Kaohsiung City, Taiwan, 80756
        • Rekruttering
        • Research Site
      • Taichung, Taiwan, 40447
        • Rekruttering
        • Research Site
      • Tainan, Taiwan, 704
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, 100
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, 112
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, 10449
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, 11259
        • Rekruttering
        • Research Site
      • Taoyuan, Taiwan, 333
        • Rekruttering
        • Research Site
      • Bangkok, Thailand, 10210
        • Rekruttering
        • Research Site
      • Bangkok, Thailand, 10400
        • Rekruttering
        • Research Site
      • Bangkok, Thailand, 10330
        • Rekruttering
        • Research Site
      • Bangkok, Thailand, 10700
        • Rekruttering
        • Research Site
      • Chiang Mai, Thailand, 50200
        • Rekruttering
        • Research Site
      • Dusit, Thailand, 10300
        • Rekruttering
        • Research Site
      • Khon Kaen, Thailand, 40002
        • Rekruttering
        • Research Site
      • Songkhla, Thailand, 90110
        • Rekruttering
        • Research Site
      • Ankara, Tyrkia (Türkiye), 6200
        • Rekruttering
        • Research Site
      • Ankara, Tyrkia (Türkiye), 06520
        • Rekruttering
        • Research Site
      • Besevler Ankara, Tyrkia (Türkiye)
        • Rekruttering
        • Research Site
      • Istanbul, Tyrkia (Türkiye), 34010
        • Rekruttering
        • Research Site
      • Izmir, Tyrkia (Türkiye), 35575
        • Tilbaketrukket
        • Research Site
      • Küçükçekmece, Tyrkia (Türkiye), 34295
        • Rekruttering
        • Research Site
      • Samsun, Tyrkia (Türkiye), 55200
        • Rekruttering
        • Research Site
      • Düsseldorf, Tyskland, 40479
        • Tilbaketrukket
        • Research Site
      • Essen, Tyskland, 45136
        • Tilbaketrukket
        • Research Site
      • Georgsmarienhütte, Tyskland, 49124
        • Tilbaketrukket
        • Research Site
      • Hamburg, Tyskland, 20357
        • Tilbaketrukket
        • Research Site
      • Hanover, Tyskland, 30625
        • Tilbaketrukket
        • Research Site
      • Heidelberg, Tyskland, 69120
        • Tilbaketrukket
        • Research Site
      • Heilbronn, Tyskland, 74078
        • Tilbaketrukket
        • Research Site
      • Leipzig, Tyskland, 04103
        • Tilbaketrukket
        • Research Site
      • Da Nang, Vietnam, 550000
        • Rekruttering
        • Research Site
      • Hanoi, Vietnam, 100000
        • Rekruttering
        • Research Site
      • Ho Chi Minh City, Vietnam, 700000
        • Rekruttering
        • Research Site
      • Huế, Vietnam, 530000
        • Rekruttering
        • Research Site
      • Hồ Chí Minh, Vietnam, 700000
        • Rekruttering
        • Research Site
      • Viet Tri, Vietnam, 35000
        • Rekruttering
        • Research Site
      • Vinh, Vietnam, 460000
        • Rekruttering
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Key Inclusion Criteria

  • Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.

  • ECOG PS 0 or 1.

  • Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. Alternatively, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start).

  • PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.

  • No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.

    - Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.

  • Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).

  • Measurable disease as per RECIST 1.1.

  • Adequate bone marrow reserve and organ function.

  • Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception.

Key Exclusion Criteria

  • As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.

  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before Cycle 1 Day 1 and of low potential risk for recurrence.

  • Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.

    - Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.

  • Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.

  • Active or uncontrolled hepatitis B or C virus infection.

  • Known HIV infection that is not well controlled.

  • Uncontrolled or significant cardiac disease.

  • History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.

  • Clinically severe pulmonary function compromise.

  • Clinically significant corneal disease.

  • Active or prior documented autoimmune or inflammatory disorders.

  • Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.

  • Any concurrent anti-cancer treatment.

  • Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.

  • Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Dato-DXd + durvalumab

Arm 1: Dato-DXd + durvalumab

Provided in 100mg vials. IV infusion. Experimental drug.

Andre navn:
  • Datopotamab deruxtecan (Dato-DXd, DS-1062a)

Provided in 500mg vials. IV infusion. Experimental drug.

Andre navn:
  • MEDI4736
Aktiv komparator: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab

Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin)

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

Eksperimentell: Dato-DXd

Arm 3: Dato-DXd

Provided in 100mg vials. IV infusion. Experimental drug.

Andre navn:
  • Datopotamab deruxtecan (Dato-DXd, DS-1062a)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression Free Survival (PFS)
Tidsramme: From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The comparison will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anticancer therapy or clinically progresses prior to RECIST 1.1 progression.

However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits.

The measure of interest is the HR of PFS.

From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Survival (OS)
Tidsramme: From randomisation until the date of death due to any cause (anticipated to be up to 64 months).

OS is defined as the time from randomisation until the date of death due to any cause.

From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
Objective Response Rate (ORR)
Tidsramme: From randomisation up until progression (anticipated to be up to 33 months).

ORR is defined as the proportion of participants who have a CR or PR, as determined by the BICR/investigator assessment, per RECIST 1.1.

From randomisation up until progression (anticipated to be up to 33 months).
Duration of Response (DoR)
Tidsramme: From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).

DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause.

From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
Progression-Free Survival (PFS) by Investigator assessment
Tidsramme: From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause.

From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
Clinical Benefit Rate (CBR) at 24 weeks
Tidsramme: From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).

CBR at 24 weeks is defined as the percentage of participants who have a CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/per investigator assessment and derived from the raw tumour data for at least 23 weeks after randomisation.

From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tidsramme: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in breast symptoms and arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration.

Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in pain in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tidsramme: Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in pain as measured by the EORTC IL199.

Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in physical functioning in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tidsramme: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
Tidsramme: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to First Subsequent Therapy (TFST)
Tidsramme: From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).

TFST is defined as the time from randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause.

From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
Time to Second Subsequent Therapy (TSST)
Tidsramme: From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).

TSST is defined as the time from randomisation until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
Progression Free Survival 2 (PFS2)
Tidsramme: From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).

PFS2 will be defined as the time from the randomisation to the earliest progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice based on radiological or clinical progression.

From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
Pharmacokinetics of Dato-DXd in combination with durvalumab
Tidsramme: From first dose to end of treatment (anticipated to be up to 33 months).

Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload) in plasma.

From first dose to end of treatment (anticipated to be up to 33 months).
Immunogenicity of Dato-DXd in combination with durvalumab
Tidsramme: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Presence of antidrug antibodies for Dato-DXd (confirmatory results: positive or negative, titres).

From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
Safety and tolerability of Dato-DXd + durvalumab as compared with ICC + pembrolizumab
Tidsramme: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Safety and tolerability will be evaluated in the safety population in terms of AEs.

From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. november 2023

Primær fullføring (Antatt)

28. juli 2027

Studiet fullført (Antatt)

30. september 2030

Datoer for studieregistrering

Først innsendt

23. oktober 2023

Først innsendt som oppfylte QC-kriteriene

23. oktober 2023

Først lagt ut (Faktiske)

27. oktober 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

25. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tilgangskriterier for IPD-deling

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere